A Phase II, Observer-Blind, Parallel Groups, Single Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine in the Previous V70P2 Study
Latest Information Update: 11 Nov 2019
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Novartis Vaccines
Most Recent Events
- 11 Nov 2019 New trial record